诺华制药(NVS.US)Q1业绩超预期上调全年增长目标

智通财经2025-04-29

智通财经APP获悉，瑞士制药商诺华制药(NVS.US)周二公布了好于预期的第一季度销售额，并上调了全年业绩指引。财报显示，按固定汇率计算，诺华制药Q1净销售额同比增长15%至132亿美元，高于分析师普遍预期的131.2亿美元。经调整后的核心营业利润达55.8亿美元，同比增长27%，远超市场预期的50.7亿美元。展望未来，诺华制药将2025年全年净销售额增长预期从原先的中高个位数上调至高个位数，核心...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2531221283?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-29 14:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531221283","market":"hk","top_or_hot":-1,"title":"诺华制药(NVS.US)Q1业绩超预期 上调全年增长目标","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，瑞士制药商诺华制药(NVS.US)周二公布了好于预期的第一季度销售额，并上调了全年业绩指引。财报显示，按固定汇率计算，诺华制药Q1净销售额同比增长15%至132亿美元，高于分析师普遍预期的131.2亿美元。经调整后的核心营业利润达55.8亿美元，同比增长27%，远超市场预期的50.7亿美元。展望未来，诺华制药将2025年全年净销售额增长预期从原先的中高个位数上调至高个位数，核心...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1287195.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺华制药(NVS.US)Q1业绩超预期 上调全年增长目标</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺华制药(NVS.US)Q1业绩超预期 上调全年增长目标\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-29 14:55 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1287195.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，瑞士制药商诺华制药(NVS.US)周二公布了好于预期的第一季度销售额，并上调了全年业绩指引。财报显示，按固定汇率计算，诺华制药Q1净销售额同比增长15%至132亿美元，高于分析师普遍预期的131.2亿美元。经调整后的核心营业利润达55.8亿美元，同比增长27%，远超市场预期的50.7亿美元。展望未来，诺华制药将2025年全年净销售额增长预期从原先的中高个位数上调至高个位数，核心...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1287195.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJJMRZ35.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1287195.html","article_id":"2531221283","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531221283","pubTimestamp":1745909708,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，瑞士制药商诺华制药周二公布了好于预期的第一季度销售额，并上调了全年业绩指引。此次业绩增长主要得益于心衰治疗药物Entresto和关节炎药物Cosentyx这两款畅销药的持续发力。此次财报发布之际，全球制药行业正密切关注美国可能加征的关税措施。继诺华制药之后，瑞士制药企业罗氏上周也宣布将在美国投资500亿美元，并创造超过1.2万个就业岗位。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","01477":"欧康维视生物-B","BK4588":"碎股","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK1574":"生物医药B类股","BK4007":"制药","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK1191":"制药","BK4532":"文艺复兴科技持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","NVS":"诺华","BK4585":"ETF&股票定投概念","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4578":"CAR-T","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC"},"translate_title":"Novartis Pharmaceuticals (NVS.US) Q1 performance exceeds expectations and raises full-year growth target","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"NVS":1},"content_text":"智通财经APP获悉，瑞士制药商诺华制药(NVS.US)周二公布了好于预期的第一季度销售额，并上调了全年业绩指引。财报显示，按固定汇率计算，诺华制药Q1净销售额同比增长15%至132亿美元，高于分析师普遍预期的131.2亿美元。经调整后的核心营业利润达55.8亿美元，同比增长27%，远超市场预期的50.7亿美元。展望未来，诺华制药将2025年全年净销售额增长预期从原先的中高个位数上调至高个位数，核心营业利润增长预期从原先的高个位数至低双位数调整为低双位数。此次业绩增长主要得益于心衰治疗药物Entresto和关节炎药物Cosentyx这两款畅销药的持续发力。但首席执行官Vas Narasimhan特别指出，乳腺癌治疗药物Kisqali、多发性硬化症药物Kesimpta以及降胆固醇药物Leqvio的市场需求正在显著增长。面对仿制药竞争压力，诺华制药正加速推进创新疗法布局。今年晚些时候，包括Entresto在内的三款核心药物将面临仿制药冲击。这对Narasimhan构成严峻考验——过去数年他持续推进战略转型，将公司资源集中于特定疾病领域的创新药物研发。首席财务官Harry Kirsch在电话会议中坦言，受仿制药竞争影响，公司下半年增速或将放缓。不过，Narasimhan在声明中表示：“包括Kisqali、Kesimpta和Leqvio在内的核心产品线保持强劲增长势头，我们预计这些产品将推动公司业绩持续增长至2030年及以后。”这位CEO还强调了公司其他药物获得的新批准，包括前列腺癌治疗药物Pluvicto。Narasimhan补充道：“我们将继续推进领先的研发管线，对实现既定增长目标充满信心。”此次财报发布之际，全球制药行业正密切关注美国可能加征的关税措施。本月早些时候，特朗普政府宣布对该行业启动调查。虽然制药产品此前一直免征全面进口关税，但特朗普在三月警告称“很快”将对特定医药产品征税。面对潜在的关税压力，欧洲制药企业正加大在美国的投资力度，以期保住这个利润丰厚的市场并优化本土化生产布局。诺华制药本月早些时候宣布，未来五年将投资230亿美元在美国新建和扩建10个生产基地，确保供应美国市场的所有关键药物都能实现本土生产。长期看好美国市场前景的Narasimhan表示，关税考量虽是企业决策因素之一，但并非主要驱动力。在本次财报中，诺华制药再次强调了其对美国、中国、德国和日本等“重点市场”的战略聚焦。继诺华制药之后，瑞士制药企业罗氏(RHHBY.US)上周也宣布将在美国投资500亿美元，并创造超过1.2万个就业岗位。与此同时，美国本土企业强生(JNJ.US)和礼来(LLY.US)近期也公布了大规模在美国的投资计划。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2531221283","isCrawlerRequest":true}

诺华制药(NVS.US)Q1业绩超预期 上调全年增长目标

精彩评论

诺华制药(NVS.US)Q1业绩超预期上调全年增长目标